Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| Eli Lilly and Company | Wistron | |
|---|---|---|
| Moat rating | wide Eli Lilly's FY2025 10-K states "Intellectual property protection is critical" and that compound patents provide roughly 20-year market exclusivity ("patents in each relevant country last for a period of 20 years"), warning that loss of patent protection causes a "severe and rapid decline in revenues." Backed by an 83.0% gross margin (up from 81.3% in 2024) and a fast-growing, patent-protected incretin franchise (Mounjaro +99%, Zepbound +175% in 2025), the economic moat is wide and durable. Source: LLY FY2025 10-K. | none The 2025 annual report (English translation filed with TWSE 2026-04-28) shows scale without a protected return: revenue of NT$2.1865 trillion, up 108%, at a gross profit margin of 6.1% and a consolidated operating profit margin of 3.6%, with gross profit up 59.33% against net revenues up 108.39%. The report's own list of unfavorable factors opens with "Intense Price Competition and Declining Gross Profit Margins" and says the IT industry, "with its relatively low barriers to entry, has attracted numerous manufacturers, leading to fierce competition", while its key-buyer table puts Buyer A at 39.32%, Buyer E at 21.21% and Buyer I at 12.81% of 2025 net sales. A large, competitive incumbent whose own filing concedes the entry barriers are relatively low: no moat is claimable. |
| Moat type | intangibles ip Per the LLY FY2025 10-K, the pharma protection "anticipated to be of most relevance" is "patents claiming the active ingredient (the compound patent)," supplemented by regulatory data protection, FDA approvals, and brands — i.e., intangible assets. The 10-K notes that without such protection, products face intense generic and biosimilar price competition that erodes revenue quickly. | none The report's "Competitive Niches" section lists operating capabilities rather than a durable barrier: an R&D team of "over 5,600 people", manufacturing bases in Taiwan, U.S.A., China, Mexico, Czech Republic, Vietnam and Malaysia, lean manufacturing, product quality, supplier relationships, global logistics and an experienced management team. None of these is a patent position or a customer lock-in: R&D expenses were 1.43% of 2025 revenue, the Company reports 120 U.S. and 122 Taiwan patents granted in 2025, and the niche section's description of brand clients "each comprising an equal share of our sales" sits beside a key-buyer table in which a single buyer took 39.32% of 2025 net sales. |
| Leadership | co leader Duopoly with Novo Nordisk: Novo's own FY2025 20-F names "Novo Nordisk and Eli Lilly [as] the most significant companies measured by market share" in the global diabetes and GLP-1 markets. Lilly is ascendant — the 20-F concedes Wegovy's years-long US anti-obesity prescription lead "was overtaken by a competing GLP-1 based product in the beginning of 2025" (Lilly's tirzepatide) — but Novo still cites Ozempic as "the leading product by sales," so co-leader is the honest band. Sources: Novo Nordisk FY2025 20-F; LLY FY2025 10-K. | at parity Citing MIC (February 2026), the report puts the Company at approximately 18% of the roughly 135,350K notebooks, 24% of the 39,711K desktops and 22% of the 12,370K servers manufactured in Taiwan in 2025, and lists it among the major Taiwan ODMs in every category it charts (notebooks with Quanta, Compal, Inventec and Pegatron; servers with Hon Hai, Quanta, Inventec and MiTAC). It describes this only as "considerable market competitiveness" and claims no first-place rank. |
| Pricing power | moderate Mixed. The LLY 10-K shows an 83.0% gross margin (up 1.7pp), evidence of strong list-price power on exclusive branded drugs; but it repeatedly notes 2025 revenue growth was "partially offset by lower realized prices" for both Mounjaro and Zepbound, alongside heavy PBM/formulary rebate pressure and default anti-obesity coverage restrictions (e.g., US self-insured employers "must generally opt in" for obesity-drug coverage). Net pricing power is therefore moderate, not strong. | weak 2025 gross profit margin was 6.1% and consolidated operating profit margin 3.6%; gross profit rose 59.33% while net revenues rose 108.39%, so the margin narrowed. The report's first unfavorable factor is "Intense Price Competition and Declining Gross Profit Margins", and three buyers accounted for 39.32%, 21.21% and 12.81% of 2025 net sales. |
| Summary | Lilly's moat rests on patent-protected, FDA-approved branded medicines led by its tirzepatide incretin franchise: per the FY2025 10-K, Mounjaro ($22.97B) and Zepbound ($13.54B) together generated roughly 56% of 2025's $65.2B revenue (up 99% and 175% respectively), while compound patents confer ~20-year market exclusivity and support an 83.0% gross margin. Durable competition only emerges after patents and regulatory data protection lapse, at which point the 10-K warns generics and biosimilars drive a "severe and rapid decline in revenues." | Wistron is a Taiwanese ODM whose business, per its 2025 annual report, "primarily covers the R&D, manufacturing, testing and after-sales services" of servers and AI computing devices, notebooks, desktops, monitors and other electronics, with 3C electronics at 98.5% of 2025 sales. Revenue more than doubled to NT$2.1865 trillion on what the Chairman's letter calls "triple-digit percentage growth in revenue from AI and general-purpose servers", and the report cites MIC data placing the Company at approximately 18% of Taiwan-made notebooks, 24% of desktops and 22% of servers in 2025. Against that, the gross profit margin was 6.1%, the report's own unfavorable factors name intense price competition, declining gross margins and relatively low barriers to entry, and three buyers took 39.32%, 21.21% and 12.81% of 2025 net sales. The long-term plan is to expand the proportion of higher-margin products such as AI computing devices and servers, and the manufacturing policy aims automation and AI-driven intelligent manufacturing at "higher-complexity, technically demanding product segments — expanding gross margins" — a stated path toward an advantage, not evidence that one exists yet. |
| Chain position | Upstream branded-drug originator. Per the FY2025 10-K, US distribution flows through three wholesalers (McKesson, Cencora, Cardinal Health), each accounting for over 10% of consolidated revenue, into consolidated PBMs/payers whose formularies and rebate demands constrain net price; Lilly is also expanding a direct-to-patient channel, LillyDirect. | Contract designer-manufacturer for brand and cloud customers: the report describes "professional OEM services supporting clients with world renowned brands", lists CPUs, SSDs and DRAM as main materials, and among its 2025 R&D results lists GPU servers supporting NVIDIA B300, AMD MI355 and Intel Gaudi 3. |
| Products (share / barrier) |
|
|
| Long-horizon vote | +0.30 at weight 0.20 · swarm neutral Editorial prior, not backtested. | -0.06 at weight 0.20 · swarm neutral Editorial prior, not backtested. |